Ubamatamab

乌巴妥单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameUbamatamab
Drug Alias NameREGN-4018
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionMucin-16 modulatorsAnti-CD3
TargetsMucin-16T cell surface glycoprotein CD3
Therapy Area/IndicationsEndometrial NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofiRegeneron Pharmaceuticals Inc
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsEndometrial NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A